Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501699 | 0.88 | TSHR (0.44) | SMN1; SMN2HPGDRAB9ANPC1LMNA | |
| SCHEMBL26501695 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2HPGDRAB9ANPC1LMNA | |
| SCHEMBL26501696 | 0.88 | SMN1; SMN2 (0.39) | SMN1; SMN2HPGDRAB9ANPC1LMNA | |
| SCHEMBL26501698 | 0.87 | TSHR (0.43) | SMN1; SMN2HPGDRAB9ANPC1LMNA | |
| SCHEMBL26501697 | 0.86 | RORC (0.41) | SMN1; SMN2HPGDRAB9ANPC1LMNA | |
| SCHEMBL26501700 | 0.82 | PTPN1 (0.40) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL26501693 | 0.81 | MAPT (0.44) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL26501551 | 0.80 | KMT2A (0.41) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL26501780 | 0.78 | USP5 (0.47) | SMN1; SMN2HPGDRAB9ANPC1LMNA | |
| SCHEMBL26501518 | 0.77 | CNR2 (0.38) | SMN1; SMN2RAB9ANPC1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | SMN1; SMN2 1609/4885HPGD 509/4885RAB9A 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.